Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059765
Filing Date
2024-05-14
Accepted
2024-05-14 17:04:45
Documents
59
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ubx-20240331.htm   iXBRL 10-Q 1828010
2 EX-31.1 ubx-ex31_1.htm EX-31.1 15779
3 EX-31.2 ubx-ex31_2.htm EX-31.2 15780
4 EX-32.1 ubx-ex32_1.htm EX-32.1 15017
  Complete submission text file 0000950170-24-059765.txt   8048778

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ubx-20240331.xsd EX-101.SCH 1447921
62 EXTRACTED XBRL INSTANCE DOCUMENT ubx-20240331_htm.xml XML 1316789
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38470 | Film No.: 24945559
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)